Defense Health Agency Contracting Activity - DHACA

Description

• Supports product-driven preclinical studies of promising novel lead agents or medical devices that have the potential to revolutionize prostate cancer clinical care. • For lead agents, PIs are expected to demonstrate within the application (1) a validated target, (2) access to either one lead agent or a limited number of lead agents for optimization, and (3) the agent’s mechanism of action. • For lead agents, preliminary data should demonstrate validated target availability and distribution in relevant human tissues and substantive information from model systems that supports potential efficacy of the lead agent(s) in humans. • For medical devices preliminary data should demonstrate reliability, reproducibility and effectiveness for the medical device. • Supports research that ranges from preclinical study through cGMP production.

Who can apply

• Unrestricted

Contact

CDMRP Help Desk: 301-682-5507
help@cdmrp.org